Pyxis Oncology Inc. Common Stock PYXS · Stock Open Pyxis Oncology Inc. Common Stock in new tab
Pyxis Oncology Inc. Common Stock Analysis (PYXS)
Is Pyxis Oncology Inc. Common Stock a good investment? Pyxis Oncology Inc. Common Stock (PYXS) is currently trading at 2.28 USD. Market analysts have a consensus price target of 6.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Pyxis Oncology Inc. Common Stock is expected to release its next earnings report on Nov. 2, 2026. The market consensus estimate for Forward EPS is -1.19.
Investor FAQ
Does Pyxis Oncology Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pyxis Oncology Inc. Common Stock?
Pyxis Oncology Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 2, 2026. The company currently has a trailing EPS of -1.59.
Company Profile
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Community Discussion